Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined
with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer
who have had neoadjuvant chemotherapy followed by initial debulking surgery.